Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Oral BG-12 (dimethyl fumarate) significantly reduced multiple sclerosis (MS) relapses and disability progression in DEFINE Phase 3 clinical trial
Pregnancy and multiple sclerosis.
A New Colour Reaction on Copper and Certain Carbonyl Compounds
Estrogen controls vitamin D3-mediated resistance to experimental autoimmune encephalomyelitis by controlling vitamin D3 metabolism and receptor expression.
Breast-feeding, postpartum and prepregnancy disease activity in multiple sclerosis.
TNF alpha promotes proliferation of oligodendrocyte progenitors and remyelination.
Biogen Idec to acquire Fumapharm AG; Consolidates ownership of oral compound BG-12 being studied for multiple sclerosis
Bidirectional cytokine interactions in the maternal-fetal relationship: is successful pregnancy a TH2 phenomenon?
Episode 12 with Professor Gavin Giovannoni on the potential for finding a cure for MS.
Extracellular Cues Influencing Oligodendrocyte Differentiation and (Re)myelination.
MRI identification of the rostral-caudal pattern of pathology within the corpus callosum in the cuprizone mouse model.
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial.
MS Research Roundup: An Introduction
Immunotherapies influence the influenza vaccination response in multiple sclerosis patients: an explorative study.
MS clinical trials: what can subgroup analyses teach us?
Cerebroside synthesis as a measure of the rate of remyelination following cuprizone-induced demyelination in brain.
Comparative efficacy of interferon β versus glatiramer acetate for relapsing-remitting multiple sclerosis.
Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Subjects With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex (SYNERGY)
Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the DEFINE study.
In vitro and in vivo pharmacological models to assess demyelination and remyelination.
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.
MS disease activity in RESTORE: A randomized 24-week natalizumab treatment interruption study.
Neuroprotective dimethyl fumarate synergizes with immunomodulatory interferon beta to provide enhanced axon protection in autoimmune neuroinflammation.
Meta-analysis of adverse events in recent randomized clinical trials for dimethil fumarate, glatiramer acetate and teriflunomide for the treatment of relapsing forms of multiple sclerosis.
Delayed visual evoked response in optic neuritis.

Pages